| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Lantheus Holdings Inc (NASDAQ: LNTH)
LNTH Technical Analysis
5
| As on 4th Dec 2025 LNTH STOCK Price closed @ 61.87 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 79.13 & Strong Sell for SHORT-TERM with Stoploss of 90.64 we also expect STOCK to react on Following IMPORTANT LEVELS. |
LNTHSTOCK Price
| Open | 59.83 | Change | Price | % |
| High | 62.60 | 1 Day | 2.10 | 3.51 |
| Low | 59.14 | 1 Week | 5.38 | 9.52 |
| Close | 61.87 | 1 Month | 4.74 | 8.30 |
| Volume | 1320580 | 1 Year | -27.40 | -30.69 |
| 52 Week High 110.01 | 52 Week Low 50.11 | ||||
NASDAQ USA Most Active Stocks
| LPTX | 2.05 | 365.91% |
| AMRS | 0.14 | 100.00% |
| WBA | 11.98 | 0.50% |
| KALA | 0.96 | 4.35% |
| NVDA | 183.38 | 2.11% |
| LMDX | 0.02 | 0.00% |
| PLUG | 2.23 | 0.00% |
| PMCB | 1.21 | 55.13% |
| ONDS | 9.19 | 3.03% |
| INTC | 40.50 | -7.45% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| LNTH Daily Charts |
LNTH Intraday Charts |
Whats New @ Bazaartrend |
LNTH Free Analysis |
|
|
LNTH Important Levels Intraday
| RESISTANCE | 68.54 |
| RESISTANCE | 66.40 |
| RESISTANCE | 65.08 |
| RESISTANCE | 63.76 |
| SUPPORT | 59.98 |
| SUPPORT | 58.66 |
| SUPPORT | 57.34 |
| SUPPORT | 55.20 |
LNTH Forecast December 2025
| 4th UP Forecast | 81.22 |
| 3rd UP Forecast | 75.01 |
| 2nd UP Forecast | 71.18 |
| 1st UP Forecast | 67.34 |
| 1st DOWN Forecast | 56.4 |
| 2nd DOWN Forecast | 52.56 |
| 3rd DOWN Forecast | 48.73 |
| 4th DOWN Forecast | 42.52 |
LNTH Weekly Forecast
| 4th UP Forecast | 75.32 |
| 3rd UP Forecast | 71.01 |
| 2nd UP Forecast | 68.34 |
| 1st UP Forecast | 65.67 |
| 1st DOWN Forecast | 58.07 |
| 2nd DOWN Forecast | 55.40 |
| 3rd DOWN Forecast | 52.73 |
| 4th DOWN Forecast | 48.42 |
LNTH Forecast2025
| 4th UP Forecast | 185.28 |
| 3rd UP Forecast | 145.7 |
| 2nd UP Forecast | 121.24 |
| 1st UP Forecast | 96.77 |
| 1st DOWN Forecast | 26.97 |
| 2nd DOWN Forecast | 2.5 |
| 3rd DOWN Forecast | -21.96 |
| 4th DOWN Forecast | -61.54 |
Lantheus Holdings Inc ( NASDAQ USA Symbol : LNTH )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
LNTH Business Profile
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; and RELISTOR for opioid-induced constipation. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical. It provides Thallium-201 to detect cardiovascular disease; Gallium-67 to detect various infections and cancerous tumors; and Quadramet for severe bone pain associated with osteoblastic metastatic bone lesions. The company also develops PyL for prostate cancer; flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroendocrine tumors; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic; 1404, a Tc-99m labeled small molecule; PSMA-AI, an AI-based imaging analysis technology; and leronlimab, an investigational humanized monoclonal antibody. It serves radiopharmacies, PET manufacturing facilities, integrated delivery networks, hospitals, clinics, and group practices. The company has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM Toyama Chemical Co. Ltd.; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts. Address: 331 Treble Cove Road, North Billerica, MA, United States, 01862
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service